ImClone Reports Positive Results From Phase II Cancer Trial
Posted on: Monday, 19 May 2008, 09:01 CDT
ImClone Systems has reported positive data from the Phase II Opus study, which show that the addition of Erbitux to Folfox chemotherapy improves both response rate and progression-free survival over Folfox alone in the first-line treatment of metastatic colorectal cancer patients whose tumors do not have mutations of the K-Ras oncogene.
The Opus study is a randomized first-line Phase II study of 337 patients comparing Erbitux plus Folfox to Folfox alone in epidermal growth factor receptor (EGFR)-expressing colorectal cancer (mCRC) patients who have not previously been treated.
Response rate, the Opus study's primary endpoint, was found to be 46% in the Erbitux-plus-Folfox arm compared with 36% in the Folfox-only arm (P = .064). When the wild type K-Ras patients are selected from the population, the response rate in the wild type K-Ras group increased to 61% in the Erbitux-plus-Folfox arm compared with 37% in the Folfox-only arm (P = .01).
With regard to the progression-free survival endpoint, the risk of disease progression was reduced by 43% (hazard ratio = 0.57; P = .02) by the addition of Erbitux to Folfox chemotherapy in wild-type K-Ras patients. The Opus study was conducted by Merck KGaA, Darmstadt, Germany.
Erbitux is a monoclonal antibody to inhibit the function of a molecular structure expressed on the surface of normal and tumor cells called the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1).
Source: Datamonitor
Related Articles
- Surgery In Patients With RA Is Often Too Late
- Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
- Study Reveals Wellness Program Enrollment Rates Vary By Industry
- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients With K-RAS or EGFR-Activated Tumours
- Treximet(TM) (Sumatriptan and Naproxen Sodium) Tablets Shown to Be Effective in Patients Who Previously Had Poor Response to, or Did Not Tolerate, Migraine Treatment With a Short-Acting Triptan
- New Booz Allen Hamilton Study Finds Consumers Are Taking More Responsibility for Health-Care Decisions, but Physicians Face Increasing Competition
- Cyberonics Announces Closure of Investigational Device Exemption (IDE) for Treatment-Resistant Depression (TRD), Lifetime Reimbursement Guarantee for All TRD IDE Study Patients and $15 Million TRD Indigent Care Program
- RenaMed Biologics Reports Positive Phase II Data With Renal Bio-Replacement Therapy; Phase II Study Results Show Improved Survival Rates in Patients With Acute Renal Failure
- Valopicitabine (NM283) Combined With Pegylated Interferon Demonstrated Significantly Greater Suppression of Hepatitis C Virus (HCV) Replication in Treatment-Refractory Patients Compared to Retreatment With Ribavirin Plus Pegylated Interferon
- Depressed Heart Surgery Patients Face Higher Mortality Rates
 |
 |
User Comments (0)
RSS Feeds